Stock VTRS VIATRIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Viatris Inc.

Equities

VTRS

US92556V1061

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 01:30:00 03/05/2024 am IST 		5-day change 1st Jan Change
11.6 USD -0.26% Intraday chart for Viatris Inc. +1.13% +7.11%
18/04 Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says MT
18/04 UK Regulator to Consider Undertakings for Theramex-Viatris Deal MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,374 22,488 16,363 13,497 12,992 13,776 - -
Enterprise Value (EV) 1 22,621 47,482 38,749 13,497 30,132 27,174 25,330 23,521
P/E ratio 670 x -16.9 x -12.9 x 6.51 x 217 x 8.36 x 13.8 x 14.9 x
Yield - - 3.33% - 4.43% 4.33% 4.51% 4.66%
Capitalization / Revenue 0.9 x 1.88 x 0.91 x 0.83 x 0.84 x 0.91 x 0.92 x 0.92 x
EV / Revenue 1.97 x 3.97 x 2.17 x 0.83 x 1.95 x 1.79 x 1.69 x 1.58 x
EV / EBITDA 6.39 x 13 x 6.03 x 2.34 x 5.88 x 5.59 x 5.41 x 5.03 x
EV / FCF 1,42,22,612 x 4,80,20,024 x 1,51,38,295 x - 1,24,37,892 x - 97,99,635 x 95,03,253 x
FCF Yield 0% 0% 0% - 0% - 0% 0%
Price to Book 0.87 x 0.49 x 0.8 x - 0.64 x 0.66 x 0.63 x 0.59 x
Nbr of stocks (in thousands) 5,16,133 12,00,000 12,09,393 12,12,685 11,99,671 11,87,569 - -
Reference price 2 20.10 18.74 13.53 11.13 10.83 11.60 11.60 11.60
Announcement Date 27/02/20 01/03/21 28/02/22 27/02/23 28/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 11,500 11,946 17,886 16,263 15,427 15,190 14,946 14,929
EBITDA 1 3,540 3,654 6,426 5,777 5,124 4,865 4,678 4,673
EBIT 1 3,264 3,376 6,046 5,475 4,724 4,543 4,480 4,499
Operating Margin 28.38% 28.26% 33.8% 33.67% 30.63% 29.9% 29.98% 30.14%
Earnings before Tax (EBT) 1 154.4 -721.2 -664.4 2,813 202.9 4,099 954.5 1,035
Net income 1 16.8 -669.9 -1,269 2,079 54.7 1,858 931.6 925
Net margin 0.15% -5.61% -7.1% 12.78% 0.35% 12.23% 6.23% 6.2%
EPS 2 0.0300 -1.110 -1.050 1.710 0.0500 1.387 0.8388 0.7811
Free Cash Flow 1,590 988.8 2,560 - 2,423 - 2,585 2,475
FCF margin 13.83% 8.28% 14.31% - 15.7% - 17.29% 16.58%
FCF Conversion (EBITDA) 44.93% 27.06% 39.83% - 47.28% - 55.25% 52.96%
FCF Conversion (Net income) 9,467.26% - - - 4,428.88% - 277.46% 267.58%
Dividend per Share 2 - - 0.4500 - 0.4800 0.5025 0.5228 0.5403
Announcement Date 27/02/20 01/03/21 28/02/22 27/02/23 28/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 4,537 4,342 4,192 4,117 4,078 3,876 3,729 3,919 3,942 3,837 3,691 3,833 3,917 3,888 3,821
EBITDA 1 1,698 1,416 1,586 1,482 1,498 1,211 1,341 1,306 1,360 1,117 1,207 1,196 1,268 1,188 -
EBIT 1 1,609 1,314 1,551 1,425 1,415 1,085 1,254 1,226 1,257 986.6 1,104 1,133 1,191 1,114 1,131
Operating Margin 35.48% 30.26% 37% 34.6% 34.7% 27.99% 33.64% 31.29% 31.89% 25.71% 29.92% 29.57% 30.4% 28.66% 29.6%
Earnings before Tax (EBT) - -203.9 527.5 - - - - - 402.2 -855 - - - - -
Net income 1 311.5 -263.8 399.2 313.9 354.3 1,011 224.7 264 331.6 -765.6 122.6 143.6 188 187.6 -
Net margin 6.87% -6.08% 9.52% 7.62% 8.69% 26.09% 6.03% 6.74% 8.41% -19.95% 3.32% 3.75% 4.8% 4.83% -
EPS 2 0.2600 -0.2200 0.3300 0.2600 0.2900 0.8300 0.1900 0.2200 0.2700 -0.6400 0.1167 0.1405 0.2291 0.3038 -
Dividend per Share 2 0.1100 0.1100 0.1200 0.1200 0.1200 - 0.1200 0.1200 0.1200 0.1200 0.1248 0.1310 0.1310 0.1373 -
Announcement Date 08/11/21 28/02/22 09/05/22 08/08/22 07/11/22 27/02/23 08/05/23 07/08/23 07/11/23 28/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,247 24,994 22,386 - 17,140 13,398 11,554 9,745
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.46 x 6.84 x 3.484 x - 3.345 x 2.754 x 2.47 x 2.085 x
Free Cash Flow 1,591 989 2,560 - 2,423 - 2,585 2,475
ROE (net income / shareholders' equity) 19% 13.6% 20.6% - 17% 14.9% 15.1% 11.1%
ROA (Net income/ Total Assets) 7.13% 5.11% -2.18% - 0.11% 6.4% 1.6% 1.8%
Assets 1 235.6 -13,110 58,189 - 48,839 29,030 58,224 51,386
Book Value Per Share 2 23.00 38.20 16.90 - 17.00 17.60 18.50 19.50
Cash Flow per Share 2 3.490 2.050 2.500 - 2.320 2.320 2.410 2.640
Capex 1 213 243 457 - 377 436 436 452
Capex / Sales 1.85% 2.03% 2.56% - 2.44% 2.87% 2.92% 3.03%
Announcement Date 27/02/20 01/03/21 28/02/22 27/02/23 28/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Viatris Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
11.6 USD
Average target price
12.46 USD
Spread / Average Target
+7.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
VIATRIS INC. Stock Viatris Inc.
+7.11% 13.78B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 325B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 235B
NOVARTIS AG Stock Novartis AG
+4.71% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VTRS Stock
  4. Financials Viatris Inc.